Local Prescribing Information (Oncology):
Atezolizumab Injection [Tecentriq®]
Bevacizumab Injection [Avastin® and Syndyma®]
Obinutuzumab Injection [Gazyva®]
Trastuzumab for Injection [Herclon™ and Biceltis®]
Trastuzumab emtansine for Injection [Kadcyla®]
Pertuzumab Injection [Perjeta®]
Rituximab Injection [Ristova® and Ikgdar®]
Alectinib Capsules [Alecensa®]
Erlotinib Tablets I.P. [Tarceva®]
Capecitabine Tablets I.P. [Xeloda®]
Safety Update Information for Healthcare Professionals (Oncology):
DHPC Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated 3rd October 2018
DHPC Tecentriq Atezolizumab Injection 1200MG/20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated July 23, 2018